Please ensure Javascript is enabled for purposes of website accessibility

Aetna Crushes Questcor: Is There Still Hope?

By Brenton Flynn – Updated Apr 7, 2017 at 12:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Questcor shareholders are left picking up the pieces after shares were nearly halved on Wednesday. The drop followed a clinical policy bulletin from insurer Aetna outlining a change in coverage policies for Questcor's flagship drug Acthar.

In an article written shortly after the news, Brenton said that shareholders had a right to be concerned about this issue, particularly the risk that more insurers would follow suit. After all, even though Aetna accounts for only around 5% of paid prescriptions of Acthar, its update largely excludes multiple sclerosis -- by far the most important indication for the drug -- from coverage going forward. If more insurers were to jump on the bandwagon, Acthar shipments could take a cliff dive.

However, Brenton feels slightly more comfortable after listening in on a call hosted by Questcor on Thursday morning. It's never bad to be skeptical of pronouncements from company managements, but in this case there were some valuable details on the dynamics at work with this drug, particularly in the MS indication.

In the following video, Brenton dives into some of that detail, as well as an interesting disclosure Questcor provides on its annual report that could have raised warning flags for investors.

Attention to the small details in annual reports can oftentimes prove the difference-maker between buying a market laggard and a stock with true multibagger potential. It's just one tool you can use in your quest to build long-term wealth and retire well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some more winning wealth-building strategies. Click here to claim your copy now.

Brenton Flynn and The Motley Fool have no positions in the stocks mentioned above. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$45.87 (0.72%) $0.33
Biogen Stock Quote
$291.41 (-0.17%) $0.49
Teva Pharmaceutical Industries Stock Quote
Teva Pharmaceutical Industries
$8.67 (0.70%) $0.06
Aetna Inc. Stock Quote
Aetna Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.